Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$111.93 USD

111.93
1,359,353

-0.62 (-0.55%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $111.94 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (161 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.

Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down

Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.

DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues

DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands

Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.

Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down

Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.

Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand

Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.

Envista (NVST) Q4 Earnings Miss Estimates, Margins Down

Strong performance in the Speciality Products & Technologies segment contributes to Envista's (NVST) Q4 revenues.

McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View

McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

STERIS (STE) Q3 Earnings Top Estimates, Fiscal '24 Sales View Up

STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.

Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down

Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.

Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?

Smart Beta ETF report for JPME

QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands

QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.

GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve

GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.

Maharathi Basu headshot

5 Broker-Loved Stocks to Watch Amid Current Market Swings

We believe that stocks like American Airlines (AAL), Delta Air Lines (DAL), Cleveland-Cliffs (CLF), Best Buy (BBY) and Cardinal Health (CAH) should be on an investor's watchlist.

Jobless Claims Increased More Than Expected

Jobless Claims Increased More Than Expected

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Mark Vickery headshot

Jobless Claims & Productivity Leap Higher; CAH, IP, HON Report

Once the market closes, we'll await earnings reports from three of the Magnificent 7 stocks: Apple, Amazon and Meta.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Should Value Investors Buy Cardinal Health (CAH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Compared to Estimates, Cardinal (CAH) Q2 Earnings: A Look at Key Metrics

The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?

Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks.com featured highlights include Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands

Axonics, Enerpac Tool Group, Cardinal Health and Acuity Brands are part of the Zacks Screen of the Week article.